Several studies suggest that PIK3CA mutations are more frequent in estrogen receptor alpha (ERα)-positive breast tumors (30–40%) than in ERα-negative breast tumors (10–20%) [7]. This evidence concerns the gene ESR1 and breast neoplasm.